Why are there so many analysts and bloggers pumping this stock?
Answer: they all plan to sell right before results are released. Textbook "Pump and Dump."
Some even admit it.
My prediction: with poor P3 results, it will plummet. With good P3 results, it will merely fall.
The biotech bubble of 2009 deflated a long time ago. While I wait for the next bubble, I will read this kind of garbage "analysis" with great amusement.
Well Funded Pluristem Adds Another Blockbuster Indication To Potent Pipeline [View article]
nice work -- THREE pump words in the title ALONE. And I see Garza is also pumping this stock. Do you guys compare notes when you plan your pump-and-dumps?
thestreet's "biotech blogger" never said Guar Diagno didn't exist. He merely said he was having trouble verifying Guar Diagno's existence. And, RPC did not say there was a new partner - biomedreports' blogger said that.
Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
success27: the Feuerstein article title is: "Mayo Clinic Denies Test Link to Radient Pharma."
You're misquoting Feuerstein. He is saying that RPC's claim of parallel testing is not verified by the Mayo Clinic.
He did not say "denied any link."
"Denies Test Link."
Pumpers are saying "when the Mayo results are released..." But there AREN'T any Mayo results. Instead, there will be RPC results done with blood samples obtained from Mayo.
"What I find interesting, it states "Onko-Sure sales for the first nine months of 2010 totaled just $116,000, down 15% from sales in the first nine months of 2009. Since the beginning of 2008, Radient has recorded $354,000 in Onko-Sure sales." So first quarter sales are already double that of the first nine months of 2010. That's impressive to me."
What are you saying? "First quarter sales are double that of the first nine months of 2010?" What 1st Qtr are you talking about? Did you misread 2008 as 2011?
Are you aware that the Korean Gvmt. was supposed to reimburse patients for onko-sure tests in 2010, and that was supposed to drive the huge revenues, in part? What happened? Why should we think India sales will be any different?
the Bhatia article confirmed that the "India $10M order" is not an order at all -- it's potential sales. You and Garza are still calling it a $10M order. Why?
Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
pinoyako - you could not be more wrong. onko-sure is cleared by the FDA for use as a monitoring test only, for patients being treated for CRC. onko sure is most assuredly NOT to be used as a screener.
I would like MacLellan to issue guidance for 4th Qtr 2010 revenues. Publicly traded companies issue this sort of guidance all the time. MacLellan knows the numbers, IMO -- Every manufacturing company in the world knows their revenue numbers daily.
2010 revenue guidance was $7.7 million, and through 3 quarters was only about $110,000. 2009 guidance also fell VERY short. MacLellan could silence his critics by reaffirming his most recent guidance that revenues would increase dramatically the second half of 2010 and the company would be "cash flow positive" in December.
I would also like to see MacLellan publicly affirm that the $10 million India deal is a sale, not a distribution agreement. Michael, you state that it's a sale, and Garza states that it's a sale, but I think you are both wrong. Please ask MacLellan to verify that (1) it's a sale, and (2) in which quarter will that $10M revenue be counted?
Radient Shares Set to Rebound Following Fall on Trading Halt Friday [View article]
RPC went up form one reason only: biomedreports pumped it.
RPC went up in April 2010 for one reason only: biomedreports pumped it. that pump proved to be hot air and fluff. Why does anyone think this pump is different?
I guess Garza is the Cramer of penny biotechs. Some made money riding the wave. Many will become bagholders.
Management forecast over $7 million revenues in 2010 -- after 3 quarters they have achieved about $110,000, and 3rd Qtr Sales at $34k were about 25% LOWER than 2nd Qtr sales of $46k.
The India deal is NOT a purchase agreement -- it's a distribution agreement. RPC has a new distribution agreement every few months. Someone agrees to try and sell Onko-Sure. To date, no one has succeeded.
Let's see some real DD, Garza. Why no mention of the defaulted loans and notes in 2009 and 2010? Why no mention of the flagging Onko-Sure sales and the grossly missed revenue forecast? Why no mention that the new formulation of Onko-Sure will need to be submitted to the FDA as a new 510(k)? Why no mention of the high rate of false positives?
CEO Tom is taking back HIS THRR Company! Naked Shorts Beware! [View instapost]
"the truly lost remain hopeless adrift in ignorance. "
so true.
This author presented conjecture as fact, and ridiculed anyone who tried to offer a logical rebuttal. He masked his agenda with flowery prose and condescending dismissal of "the bashers."
As it turns out, this author was wrong on every count.
Tom Takes Back HIS Company or Caveat Emptor to the Naked Shorters! [View instapost]
I wonder how many people you hurt with this flowery garbage.
your grammar is horrible, your condescending tone irritating, your wrtiting style amateurish, and your logic comical at times, insulting at others... you offer no real facts, only conjecture... but worst of all... you mock the "bashers" who turned out to be right all along.
Anyone who isn't aware: the buyout turned out to be a scam after all.
Acadia's Bubbling To Move Higher [View article]
Answer: they all plan to sell right before results are released. Textbook "Pump and Dump."
Some even admit it.
My prediction: with poor P3 results, it will plummet. With good P3 results, it will merely fall.
The biotech bubble of 2009 deflated a long time ago. While I wait for the next bubble, I will read this kind of garbage "analysis" with great amusement.
Well Funded Pluristem Adds Another Blockbuster Indication To Potent Pipeline [View article]
Adventrx CEO Attempting To Prime His Firm For A Comeback [View article]
it's down 99% since you last pumped it. Don't you think an explanation is in order? Thanks in Advance.
Regarding latest 8k filing by Radient Pharmaceuticals- $RPC [View instapost]
TIA
Stocks to Watch This Week [View article]
Your "reporting" is not reporting at all, is it?
Cardium Therapeutics, Lannett: Dealing With Debilitating Biotech Situations [View article]
Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
You're misquoting Feuerstein. He is saying that RPC's claim of parallel testing is not verified by the Mayo Clinic.
He did not say "denied any link."
"Denies Test Link."
Pumpers are saying "when the Mayo results are released..." But there AREN'T any Mayo results. Instead, there will be RPC results done with blood samples obtained from Mayo.
The Mayo verified Feuerstein's evidence:
dev.newsblog.mayoclini.../
and Michael: above you say:
"What I find interesting, it states "Onko-Sure sales for the first nine months of 2010 totaled just $116,000, down 15% from sales in the first nine months of 2009. Since the beginning of 2008, Radient has recorded $354,000 in Onko-Sure sales." So first quarter sales are already double that of the first nine months of 2010. That's impressive to me."
What are you saying? "First quarter sales are double that of the first nine months of 2010?" What 1st Qtr are you talking about? Did you misread 2008 as 2011?
Are you aware that the Korean Gvmt. was supposed to reimburse patients for onko-sure tests in 2010, and that was supposed to drive the huge revenues, in part? What happened? Why should we think India sales will be any different?
the Bhatia article confirmed that the "India $10M order" is not an order at all -- it's potential sales. You and Garza are still calling it a $10M order. Why?
biomedreports.com/2011...
"Based on response to initial program outreach, GDL now estimates Onko-Sure test kit usage could potentially reach 25,000 in FY 2011."
"An initial Onko-Sure order for the broad cancer screening programs is anticipated by the end of Q1 2011."
Radient Pharmaceuticals: Betting on Bullish Earnings and Positive Study Results [View article]
I would like MacLellan to issue guidance for 4th Qtr 2010 revenues. Publicly traded companies issue this sort of guidance all the time. MacLellan knows the numbers, IMO -- Every manufacturing company in the world knows their revenue numbers daily.
2010 revenue guidance was $7.7 million, and through 3 quarters was only about $110,000. 2009 guidance also fell VERY short. MacLellan could silence his critics by reaffirming his most recent guidance that revenues would increase dramatically the second half of 2010 and the company would be "cash flow positive" in December.
I would also like to see MacLellan publicly affirm that the $10 million India deal is a sale, not a distribution agreement. Michael, you state that it's a sale, and Garza states that it's a sale, but I think you are both wrong. Please ask MacLellan to verify that (1) it's a sale, and (2) in which quarter will that $10M revenue be counted?
TIA
Radient Shares Set to Rebound Following Fall on Trading Halt Friday [View article]
RPC went up in April 2010 for one reason only: biomedreports pumped it. that pump proved to be hot air and fluff. Why does anyone think this pump is different?
I guess Garza is the Cramer of penny biotechs. Some made money riding the wave. Many will become bagholders.
Management forecast over $7 million revenues in 2010 -- after 3 quarters they have achieved about $110,000, and 3rd Qtr Sales at $34k were about 25% LOWER than 2nd Qtr sales of $46k.
The India deal is NOT a purchase agreement -- it's a distribution agreement. RPC has a new distribution agreement every few months. Someone agrees to try and sell Onko-Sure. To date, no one has succeeded.
Let's see some real DD, Garza. Why no mention of the defaulted loans and notes in 2009 and 2010? Why no mention of the flagging Onko-Sure sales and the grossly missed revenue forecast? Why no mention that the new formulation of Onko-Sure will need to be submitted to the FDA as a new 510(k)? Why no mention of the high rate of false positives?
CEO Tom is taking back HIS THRR Company! Naked Shorts Beware! [View instapost]
so true.
This author presented conjecture as fact, and ridiculed anyone who tried to offer a logical rebuttal. He masked his agenda with flowery prose and condescending dismissal of "the bashers."
As it turns out, this author was wrong on every count.
Tom Takes Back HIS Company or Caveat Emptor to the Naked Shorters! [View instapost]
your grammar is horrible, your condescending tone irritating, your wrtiting style amateurish, and your logic comical at times, insulting at others... you offer no real facts, only conjecture... but worst of all... you mock the "bashers" who turned out to be right all along.
Anyone who isn't aware: the buyout turned out to be a scam after all.